Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIUS: Midostaurin post-HSCT in FLT3-ITD AML
NCT01883362Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Standard of Care with Midostaurin with Standard of Care (2 arms). Primary endpoint: Relapse Free Survival at 18 months. Started Feb 2014; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01883362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883362.